TMTatsuya Minami

Tatsuya Minami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatsuya Minami has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid Intrasegmental Progression After Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma: Incidence, Imaging Features, and Clinical Outcomes

    by Takuma Kaneko, Takuma Nakatsuka, Ryosuke Tateishi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Tatsuya Minami, Masaya Sato, Mitsuhiro Fujishiro

    Aim: Radiofrequency ablation (RFA) is curative therapy for early‐stage hepatocellular carcinoma (HCC), but a rare subset of patients develop aggressive intrasegmental recurrence shortly after complete ablation. We characterized the incidence, risk factors, and absolute risk. Methods: This single‐center retrospective study included consecutive patients with HCC treated with RFA from August 2002 to December 2024. Rapid progression was defined as recurrence at the ablation margin within 6 months that precluded further locoregional therapy. Cases were matched 1 to 4 with controls based on treatment era, prior RFA sessions, tumor diameter, and tumor number. Preablation imaging and tumor marker dynamics were compared, and absolute risk was estimated. Results: Among 3163 patients who underwent 10,240 RFA treatments, 20 (0.20%) met criteria for rapid progression. Aggressive imaging features including nonsmooth margins (OR 5.87, 95% CI 1.80–19.12) and multinodular confluent growth (OR 3.84, 95% CI 1.30–11.36) were significantly more common in the rapid progression group, though positive predictive values remained below 1%. Irregular rim‐like hyperenhancement was present in 15% of rapid progression cases but was absent in all controls. Periportal location accounted for half of the rapid progression cases (OR 2.84, 95% CI 0.97–8.29). Tumor markers including alpha‐fetoprotein and des‐gamma‐carboxy prothrombin declined after RFA in controls but not in the rapid progression group. Conclusions: Aggressive imaging features and insufficient post‐ablation tumor marker decline were associated with rapid progression, though individual predictive value was low. Tumor marker trends may help guide surveillance and earlier transition to systemic therapy.

  • Open Access

    Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals

    by Tsuyoshi Fukumoto, Tatsuya Minami, Makoto Moriyama, Tomoharu Yamada, Taijiro Wake, Mizuki Nishibatake Kinoshita, Naoto Fujiwara, Ryo Nakagomi, Takuma Nakatsuka, Masaya Sato, et al.

    The prognostic impact of direct‐acting antivirals (DAAs) on patients with hepatitis C‐related hepatocellular carcinoma (C‐HCC) is still unclear. This study aimed to evaluate the prognosis of C‐HCC in the DAA era. We enrolled 1237 consecutive patients with treatment‐naive C‐HCC who underwent radical radiofrequency ablation between 1999 and 2019. We also enrolled 350 patients with nonviral HCC as controls. We divided these patients into three groups according to the year of initial treatment: 1999–2005 (cohort 1), 2006–2013 (cohort 2), and 2014–2019 (cohort 3). The use of antiviral agents and their effect in patients with C‐HCC was investigated. Overall survival was evaluated for each cohort using the Kaplan‐Meier method and a multivariable Cox proportional hazards regression model. Sustained virologic response (SVR) was achieved in 52 (10%), 157 (26%), and 102 (74%) patients with C‐HCC in cohorts 1–3, respectively. The 3‐ and 5‐year survival rates of patients with C‐HCC were 82% and 59% in cohort 1; 80% and 64% in cohort 2; and 86% and 78% in cohort 3, respectively (p = 0.003). Multivariable analysis adjusted for age, liver function, and tumor extension showed that the prognosis of C‐HCC improved in cohort 3 compared to cohort 1 (adjusted hazard ratio [aHR], 0.49; 95% confidence interval [CI], 0.32–0.73; p < 0.001), whereas the prognosis of nonviral HCC did not improve significantly (aHR, 0.96; 95% CI, 0.59–1.57; p = 0.88). The prognosis of C‐HCC drastically improved with the advent of DAAs.


  • Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

    by Victor Sapena, Marco Enea, Ferran Torres, Ciro Celsa, Jose Rios, Giacomo Emanuele Maria Rizzo, Pierre Nahon, Zoe Mariño, Ryosuke Tateishi, Tatsuya Minami, et al.

    Objective: The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. Design: We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. Results: Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I 2 =74.6%) and 5.7 (2.5 to 15.3, I 2 =54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1). Conclusion: Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.


  • Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

    by Fanpu Ji, Yee Hui Yeo, Mike Tzuhen Wei, Eiichi Ogawa, Masaru Enomoto, Dong Hyun Lee, Etsuko Iio, John Lubel, Wenjun Wang, Bin Wei, et al.


  • Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy

    by Mizuki Nishibatake Kinoshita, Tatsuya Minami, Ryosuke Tateishi, Taijiro Wake, Ryo Nakagomi, Naoto Fujiwara, Masaya Sato, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, et al.


  • Open Access

    Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation

    by Koji Uchino, Ryosuke Tateishi, Ryo Nakagomi, Naoto Fujiwara, Tatsuya Minami, Masaya Sato, Kenichiro Enooku, Hayato Nakagawa, Yoshinari Asaoka, Yuji Kondo, et al.

    Hepatic iron accumulation can accelerate liver injury in patients with various chronic liver diseases and lead to hepatocarcinogenesis. We elucidated the impact of serum levels of ferritin on the prognosis of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) in a large cohort. We retrospectively analyzed 578 treatment-naïve HCC patients who underwent RFA. We divided our cohort into four groups by the quartile points of serum ferritin level: G1 (≤55 ng/mL, n = 148), G2 (56–130 ng/mL, n = 142), G3 (131–243 ng/mL, n = 144) and G4 (≥244 ng/mL, n = 144). We analyzed the recurrence and survival of patients using the Kaplan–Meier method. We also evaluated pathological iron deposition among patients with a solitary tumor smaller than 2 cm. The cumulative rates of overall recurrence and survival at 5 years were 81.6% and 66.3%, respectively. The serum levels of ferritin were correlated with pathological iron deposition. There were no significant differences in recurrence and survival rates according to serum levels of ferritin and pathological hepatic iron deposition. Serum levels of ferritin do not affect the prognosis of HCC patients undergoing RFA.


  • Open Access

    Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients

    by Koji Uchino, Ryosuke Tateishi, Naoto Fujiwara, Tatsuya Minami, Masaya Sato, Kenichiro Enooku, Hayato Nakagawa, Yoshinari Asaoka, Yuji Kondo, Haruhiko Yoshida, et al.


  • Open Access

    Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma

    by Yoshinari Asaoka, Ryosuke Tateishi, Ryo Nakagomi, Mayuko Kondo, Naoto Fujiwara, Tatsuya Minami, Masaya Sato, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, et al.

    Vascular invasion in patients with hepatocellular carcinoma (HCC) is representative of advanced disease with an extremely poor prognosis. The detailed course of its development has not been fully elucidated. We enrolled 1057 consecutive patients with HCC who had been treated with curative intent by radiofrequency ablation (RFA) as an initial therapy from 1999 to 2008 at our department. We analyzed the incidence rate of and predictive factors for vascular invasion. The survival rate after detection of vascular invasion was also analyzed. During a mean follow-up period of 4.5 years, 6075 nodules including primary and recurrent lesions were treated by RFA. Vascular invasion was observed in 97 patients. The rate of vascular invasion associated with site of original RFA procedure was 0.66% on a nodule basis. The incidence rates of vascular invasion on a patient basis at 1, 3, and 5 years were 1.1%, 5.9%, and 10.4%, respectively. Univariate analysis revealed that tumor size, tumor number, alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein were significant risk predictors of vascular invasion. In multivariate analysis, DCP was the most significant predictor for vascular invasion (compared with a DCP of ≤100 mAu/mL, the hazard ratio was 1.95 when DCP was 101–200 mAu/mL and 3.22 when DCP was >200 mAu/mL). The median survival time after development of vascular invasion was only 6 months. Vascular invasion occurs during the clinical course of patients initially treated with curative intent. High-risk patients may be identified using tumor markers.